Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘cell cycle retractions’ Category

University of Tokyo opens investigation into retracted stem cell paper

without comments

KCCY_15_22_COVER.inddThe University of Tokyo is investigating a 2011 stem cell paper in Cell Cycle, recently retracted over irregularities in four figures.

The university has confirmed there is an investigation, but would not specify which paper it concerned; the corresponding author on the paper, however, confirmed to us that it is the focus of the investigation.

In the retraction notice, published Nov. 1, the journal wrote: Read the rest of this entry »

Geneticist retracting four papers for “significant problems”

with 25 comments

jbc 620Benjamin Barré, a genetics researcher who recently set up his own group at the University of Angers, is retracting four papers he worked on as a graduate student and postdoc.

Neil Perkins, in whose lab Barré was a postdoc, and Olivier Coqueret, in whose lab he did his PhD, tell Retraction Watch: Read the rest of this entry »

Not our problem: Journal bows out of data dispute after U Minn challenges previous statement

without comments

cellcyclecoverBack in May we reported on an Expression of Concern in Cell Cycle — a notice that had entered life as a retraction but mysteriously metamorphosed into the less dramatic form. The statement limned a rather bizarre dispute between researchers who crossed paths at the University of Minnesota and are now embroiled in litigation over ownership of the data.

Now, it gets weirder. Responding to further correspondence from the university, the journal has effectively washed its hands of the matter — without bothering to wipe down the sink or hang up the towel.

Here’s the “Comment on Expression of Concern“: Read the rest of this entry »

Amid a legal dispute, journal downgrades a retraction to an expression of concern

without comments

cellcyclecoverThe journal Cell Cycle is expressing a “note” of concern about a 2012 paper by a former researcher at the University of Minnesota, who has claimed that her mentor at the institution was violating her copyright. It turns out the journal had briefly retracted the paper, but reversed itself with the expression of concern — a curious about-face that, in our experience, often indicates the work of lawyers.

That seems to be the case here, too.

The article, “Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes,” was already the subject of an erratum, available here:

Read the rest of this entry »

Another G&D paper retracted, this one for faked data

with one comment

Genes & Development (G&D) — a journal published by Cold Spring Harbor Laboratory that published only its second retraction in its 24-year history a few weeks ago, has published another. The study, “PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling,” was published in 2009 and has been cited 22 times, according to Thomson Scientific’s Web of Knowledge.

The retraction notice places the blame squarely on first author Susanne Weber, who was a graduate student at the time the study was published and signed the retraction. The G&D notice, in the July 1, 2011 issue, reads: Read the rest of this entry »

Update: After unexplained delay, Cell Cycle retracts paper related to work that formed the basis of anti-cancer company

with one comment

In December, we reported on the retraction of a paper in the Proceedings of the National Academy of Sciences on a potential treatment for breast cancer. We later found out that the retracted research was part of the basis of a company that had an initial public offering a few weeks later. How the company dealt with the news of the retraction made for an interesting follow-up, and speaks well of the principles of the principals.

Here’s another follow-up. The retraction notice has now appeared of a related review in Cell Cycle that we reported would be withdrawn. Here’s the text: Read the rest of this entry »

Written by Ivan Oransky

April 22nd, 2011 at 2:00 pm

Wnt Research: How a retraction delayed an IPO, shrunk investment — but should build public trust

with 2 comments

It’s easy to focus on the downstream scientific effects of retractions. But sometimes they have financial implications, too.

Two weeks ago, we covered the retraction of a PNAS paper on a potential breast cancer treatment, one that would make tumors that didn’t respond to tamoxifen respond to the drug. We learned earlier this week from a Retraction Watch commenter that Wnt Research, a company based on the breast cancer finding and other work, was about to go public.

In fact, their initial public offering (IPO) happened today, and you can follow the price of their stock — listed on the Stockholm Stock Exchange as WNT — here. But what we learned when we looked into the IPO was that it was originally scheduled for late November, and was delayed because of the retraction.

Tommy Andersson, one of the researchers on the now-retracted paper and Wnt Research’s chief scientific officer, told Retraction Watch that the company had initially planned on going public on November 26. They had written a memorandum describing the company’s work to date, and its plans, and the public was given a chance to invest before shares hit the Stockholm exchange. That memorandum included a mention of the PNAS paper, as follows (translated from Swedish): Read the rest of this entry »

Written by Ivan Oransky

December 17th, 2010 at 11:50 am

PNAS paper on potential breast cancer treatment retracted

with 3 comments

The authors of a 2009 study in the Proceedings of the National Academy of Sciences (PNAS) have retracted the paper, which found a particular molecule could make breast tumors respond to a drug to which they’re not normally susceptible.

The paper — which has been cited five times, according to Thomson Scientific’s Web of Knowledge — was the subject of a fair amount of press coverage, although the molecule is not yet in clinical trials. In a Reuters story, lead author Caroline Ford said of the alleged tamoxifen-sensitizing compound, Foxy-5:

“It flips the switch basically,” Ford said in a telephone interview. “It makes breast cancer cells respond to tamoxifen in women who cannot be treated with the drug,” she added. “If you don’t have that molecule you can’t get tamoxifen because there is no target.”

According to the retraction notice, signed by all three of the study’s authors: Read the rest of this entry »

Written by Ivan Oransky

December 3rd, 2010 at 9:30 am